Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence

ClinicalTrials.gov ID: NCT00981617

Public ClinicalTrials.gov record NCT00981617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Adaptive Study of the Safety and Efficacy of RDC-0313 in Adults With Alcohol Dependence

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety and efficacy of ALKS33 (RDC-0313) compared with placebo in adults with alcohol dependence. There will be 11 study visits conducted over a period of about 4 months. The study period includes a screening visit, a 12-week treatment period, and a follow-up visit.

Study identification

NCT ID
NCT00981617
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Alkermes, Inc.
Industry
Enrollment
406 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2009
Primary completion
Jul 31, 2010
Completion
Jul 31, 2010
Last update posted
Aug 22, 2011

2009 – 2010

United States locations

U.S. sites
27
U.S. states
15
U.S. cities
26
Facility City State ZIP Site status
Alkermes Investigational Site Tucson Arizona 85712
Alkermes Investigational Site Cerritos California 90703
Alkermes Investigational Site Oceanside California 92056
Alkermes Investigational Site Pico Rivera California 90660
Alkermes Investigational Site San Diego California 92102
Alkermes Investigational Site Jacksonville Florida 32216
Alkermes Investigational Site Maitland Florida 32751
Alkermes Investigational Site Orlando Florida 32806
Alkermes Investigational Site South Miami Florida 33143
Alkermes Investigational Site West Palm Beach Florida 33407
Alkermes Investigational Site Atlanta Georgia 30320
Alkermes Investigational Site Atlanta Georgia 30328
Alkermes Investigational Site Roswell Georgia 30076
Alkermes Investigational Site Lafayette Indiana 47905
Alkermes Investigational Site Fall River Massachusetts 02720
Alkermes Investigational Site Las Vegas Nevada 89146
Alkermes Investigational Site Albuquerque New Mexico 87102
Alkermes Investigational Site Brooklyn New York 11235
Alkermes Investigational Site New York New York 10010
Alkermes Investigational Site Charlotte North Carolina 28209
Alkermes Investigational site Hickory North Carolina 28601
Alkermes Investigational Site New Bern North Carolina 28562
Alkermes Investigational Site Oklahoma City Oklahoma 73103
Alkermes Investigational Site Philadelphia Pennsylvania 19118
Alkermes Investigational Site Houston Texas 77090
Alkermes Investigational Site Salt Lake City Utah 84107
Alkermes Investigational Site Middleton Wisconsin 53562

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00981617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 22, 2011 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00981617 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →